LAB Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
19.4M
-3.6%
20.1M
-4.9%
21.1M
-11.1%
23.8M
+21.7%
19.6M
Cost of Revenue
8.6M
-10.6%
9.6M
-2.7%
9.8M
-20.7%
12.4M
+23.3%
10.1M
Gross Profit
10.8M
+2.8%
10.5M
-6.8%
11.3M
-0.7%
11.4M
+20.0%
9.5M
Operating Expenses
30.6M
-14.8%
35.9M
+50.9%
23.8M
-33.9%
36.0M
-15.1%
42.4M
R&D
2.1M
+5.2%
2.0M
-6.7%
2.1M
-73.4%
8.0M
+25.4%
6.4M
SG&A
16.8M
+2.8%
16.4M
-11.9%
18.6M
-26.6%
25.3M
-4.7%
26.6M
Operating Income
-19768000
+22.1%
-25388000
-103.2%
-12496000
+49.3%
-24644000
+25.2%
-32938000
EBITDA
-6890000
-5.1%
-6556000
+18.1%
-8008000
+61.2%
-20633000
+6.0%
-21946000
Net Income
13.5M
+150.4%
-26758000
-121.1%
127.1M
+559.0%
19.3M
+155.6%
-34687000
EPS (Basic)
$0.03
+142.9%
$-0.07
-121.2%
$0.33
+560.0%
$0.05
+155.6%
$-0.09
EPS (Diluted)
$0.03
+142.9%
$-0.07
-121.2%
$0.33
+560.0%
$0.05
+155.6%
$-0.09
Shares (Diluted)
393.6M
+0.7%
390.9M
+0.7%
388.2M
+0.8%
385.1M
+0.7%
382.6M
Standard BioTools (LAB) — Financials